Biogen’s Alzheimer’s Drug Aduhelm Has Another Shot at Success

Illustration by Elias Stein Text size Biogen ’s Alzheimer’s disease therapy, Aduhelm, has been a disappointment for the company since its Food and Drug Administration approval last spring, with early ...

Rio Tinto Is Building Its Lithium Business. The Move to Green Energy Will Boost the Stock.

Diversified miner Rio Tinto is pivoting toward clean-energy products. Courtesy of Rio Tinto Text size A fat dividend and a robust pivot toward clean-energy products should make United Kingdom–based di...

Opinion: Social Security blows it again

Social Security had another disastrous financial year in 2022 even as it hurtles toward insolvency. America’s main pension plan saw its investments badly trail the booming markets, competitors, and ev...

The $2 Trillion Cryptocurrency Market Is Drawing Interest From Investors, Scrutiny From U.S. Regulators

WASHINGTON—As cryptocurrencies go mainstream, prices for bitcoin and other digital tokens are often displayed on cable-news tickers and finance apps as though they were just like regular stocks, bonds...

The Warren-Biden Bank Heist – WSJ

Elizabeth Warren finally got her woman—that is, the Senator and her many acolytes in the Biden Administration have succeeded in ousting Jelena McWilliams as chair of the Federal Deposit Insurance Corp...

Weekend reads: Your money and how to invest in 2022

Happy New Year! As 2021 ends, we once again hope for the new year will bring a pandemic recovery. Here are some looks ahead at what may affect financial markets, companies and even you in 2022. Turn a...

While FuelCell Earnings Disappointed, Some Analysts Still See an Upside

Text size A hydrogen fuel-cell powered tractor Jung Yeon-je / AFP via Getty Images Shares of FuelCell Energy were rallying Thursday even though fourth-quarter earnings disappointed Wall Street, prompt...